Alpha cognition inc. announces pricing of $35 million oversubscribed public offering of common shares

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (the “company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. the gross proceeds of the offering are approximately $35.0 million, befor.
ACOG Ratings Summary
ACOG Quant Ranking